Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

[Inpatient rheumatology treatment in Germany].

Kekow J.

Z Rheumatol. 2014 Mar;73(2):135-8. doi: 10.1007/s00393-013-1261-3. German.

PMID:
24659149
2.

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.

Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A.

Ann Rheum Dis. 2015 Feb;74(2):415-21. doi: 10.1136/annrheumdis-2013-204021. Epub 2013 Nov 29.

3.

Long-term persistence and effects of fetal microchimerisms on disease onset and status in a cohort of women with rheumatoid arthritis and systemic lupus erythematosus.

Kekow M, Barleben M, Drynda S, Jakubiczka S, Kekow J, Brune T.

BMC Musculoskelet Disord. 2013 Nov 18;14:325. doi: 10.1186/1471-2474-14-325.

4.

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure.

Kekow J, Mueller-Ladner U, Schulze-Koops H.

Biologics. 2012;6:191-9. doi: 10.2147/BTT.S32244. Epub 2012 Jul 2.

5.

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group.

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.

PMID:
21542001
6.

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.

Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1):26-34. Epub 2011 Feb 23.

PMID:
21345289
7.

Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.

Ma YL, Marin F, Stepan J, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Martínez G, Malouf J, Zeng QQ, Wan X, Recker RR.

Bone. 2011 May 1;48(5):972-8. doi: 10.1016/j.bone.2011.01.012. Epub 2011 Jan 22.

PMID:
21262402
8.

[Diagnostic spectrum, treatment indication and symptom duration in initial referrals to the rheumatologist].

Westhoff G, Edelmann E, Kekow J, Zink A.

Z Rheumatol. 2010 Dec;69(10):910-8. doi: 10.1007/s00393-010-0715-0. German.

PMID:
21088969
9.

Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.

Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A.

Rheumatology (Oxford). 2011 Feb;50(2):401-9. doi: 10.1093/rheumatology/keq327. Epub 2010 Nov 8.

10.

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group.

Osteoporos Int. 2011 Jun;22(6):1935-46. doi: 10.1007/s00198-010-1379-y. Epub 2010 Oct 12.

11.

Rheumatoid pneumoconiosis (Caplan's syndrome).

Schreiber J, Koschel D, Kekow J, Waldburg N, Goette A, Merget R.

Eur J Intern Med. 2010 Jun;21(3):168-72. doi: 10.1016/j.ejim.2010.02.004. Epub 2010 Mar 2. Review.

PMID:
20493416
12.

Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.

Lyritis G, Marin F, Barker C, Pfeifer M, Farrerons J, Brixen K, del Pino J, Keen R, Nickelsen TN; EUROFORS Study Group.

Curr Med Res Opin. 2010 Aug;26(8):1799-807. doi: 10.1185/03007995.2010.488516.

PMID:
20482322
13.

Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study.

Assmann G, Koenig J, Pfreundschuh M, Epplen JT, Kekow J, Roemer K, Wieczorek S.

J Rheumatol. 2010 May;37(5):900-4. doi: 10.3899/jrheum.091110. Epub 2010 Mar 15.

PMID:
20231205
14.

["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept].

Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkühn T, Radke M, Reich K, Rudwaleit M, Schreiber S.

Dtsch Med Wochenschr. 2009 Oct;134(42):2132-6. doi: 10.1055/s-0029-1242011. Epub 2009 Oct 6. Review. German.

PMID:
19809965
15.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial.

Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3.

PMID:
19802508
16.

[Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors].

Franck H; Kommission Osteologie der Deutschen Gesellschaft für Rheumatologie, Braun J, Buttgereit F, Demary W, Hein G, Kekow J, Schett G, Kern PM.

Z Rheumatol. 2009 Dec;68(10):845-50. doi: 10.1007/s00393-009-0502-y. Review. German.

PMID:
19714343
17.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

PMID:
19567517
18.

MS characterization of apheresis samples from rheumatoid arthritis patients for the improvement of immunoadsorption therapy - a pilot study.

Kienbaum M, Koy C, Montgomery HV, Drynda S, Lorenz P, Illges H, Tanaka K, Kekow J, Guthke R, Thiesen HJ, Glocker MO.

Proteomics Clin Appl. 2009 Jul;3(7):797-809. doi: 10.1002/prca.200800232.

PMID:
21136988
19.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

PMID:
19560810
20.

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J.

J Bone Miner Res. 2009 Aug;24(8):1358-68. doi: 10.1359/jbmr.090315.

PMID:
19338452
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk